Logo Takeda

Contact information

Tigenix, SAU
Pilar Redondo, Site Head
Marconi, 1. Parque Tecnológico de Madrid
Tres Cantos
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biodrugs
      • Stem cells
      • Cellular Therapy
    • Therapeutic areas
      • Dermatology
      • Musculoskeletal system
      • Inflammatory diseases
      • Immunology
      • Digestive system and hepatology
  • C. Industrial Biotechnology
    • Cell lines

TiGenix SAU (Takeda group), is a technological center that includes a production plant for Alofisel, an allogeneic cell therapy drug (from donors) for the treatment of patients with Crohn's disease who suffer from complex perianal fistulas. TiGenix is headquartered in Tres Cantos – Madrid.

Products and services

The company?s lead product, ChondroCelect, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched across Europe. TiGenix?s adipose derived allogeneic stem cell platform has been extensively validated: Cx601, Phase III clinical trial to treat complex perianal fistula in patients with Crohn?s, a Phase IIa trial in rheumatoid arthritis ongoing, and a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders.